T1107 polymer expressed potential anti-tumor effects against HepG2 cell line

Background : Polymeric nanoparticles (NPs) are obtained naturally, semi-synthetically or synthetically by a polymerization reaction. Tetronics based ethylene oxide-propylene oxide copolymers have gained a great of interest. It demonstrated interactions with cell membranes with potential for developing new biomaterials for application in nanomedicine . Aim: The primary aim of the current study is to test the direct anticancer activity of unmodified tetronic (T1107), P-HB+aminated tetronic and N, N DMAB+aminated tetronic polymersand the associated by apoptosis and cell cycle. Materials and Methods : Synthetic polymers were prepared and characterized to confirm the modification. Antitumor activity was examined in vitro using human hepatocellular carcinoma (HepG2) cell line. Cell viability (MTT), cell cycle and apoptosis were evaluated by flow cytometry. Results : Unmodified tetronic (T1107) decreased HepG2 viability (by 30%) than untreated HepG2 cells. Treatment with P-HB+aminated tetronic and N,N DMAB+aminated did not give a significant effect on Hepg-2 cells. Treatment of HepG2 with unmodified tetronic (T1107) induced cell cycle arrest at G0 phase (39.4%), while P-HB+aminated tetronic and N,N DMAB+aminated tetronic induced cell cycle arrest at G1 phase (by 54.8% and 48.2%, respectively as compared to treatment with the doxorubicin (DOX) as a reference drug, which induced Hepg-2 cell cycle arrest at GO phase (by 39.1%). The unmodified tetronic (T1107) increased the numbers of late apoptotic cells (by 49.4%), while P-HB+aminated tetronic and N,N DMAB+aminated tetronic did not induced significant apoptosis. Conclusion :.Unmodified Tetronic T1107 induces an anticancer effect more than modified Tetronic polymers.